Literature DB >> 29477993

First case of acute granulomatous interstitial nephritis with immune reconstitution inflammatory syndrome in a patient with HIV coinfected with disseminated Mycobacterium kansasii.

Vikas Kapoor1, Azka Latif1, Faiza Hassan Warraich1, Aneela Majeed2.   

Abstract

Restoration of immune response by highly active antiretroviral therapy (HAART) effectively improved the overall prognosis of HIV infection. However, 25%-31.7% of patients experience paradoxical worsening of pre-existing infections or unmasking of subclinical infections after starting HAART therapy, which is termed as immune reconstitution inflammatory syndrome (IRIS). Acute granulomatous interstitial nephritis as a consequence of IRIS has never been reported with Mycobacteriumkansasiicoinfection. Here, we describe an HIV/AIDS patient coinfected with disseminated M. kansasii infection, who presented with acute kidney injury 4.5 months after initiation of HAART. The diagnostic workup revealed IRIS was the cause of acute kidney injury. Short-term course of prednisone (1 mg/kg/day) along with antimycobacterial and HAART regimen achieved significant improvement. © BMJ Publishing Group Ltd (unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  acute renal failure; immunology; infections; infectious diseases

Mesh:

Substances:

Year:  2018        PMID: 29477993      PMCID: PMC5847901          DOI: 10.1136/bcr-2017-222149

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  8 in total

Review 1.  Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy.

Authors:  Samuel A Shelburne; Richard J Hamill; Maria C Rodriguez-Barradas; Stephen B Greenberg; Robert L Atmar; Daniel W Musher; Joseph C Gathe; Fehmida Visnegarwala; Barbara W Trautner
Journal:  Medicine (Baltimore)       Date:  2002-05       Impact factor: 1.889

2.  Outcome of HIV-associated tuberculosis in the era of highly active antiretroviral therapy.

Authors:  Keertan Dheda; Fiona C Lampe; Margaret A Johnson; Marc C Lipman
Journal:  J Infect Dis       Date:  2004-09-29       Impact factor: 5.226

Review 3.  Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis.

Authors:  Monika Müller; Simon Wandel; Robert Colebunders; Suzanna Attia; Hansjakob Furrer; Matthias Egger
Journal:  Lancet Infect Dis       Date:  2010-04       Impact factor: 25.071

4.  Thymopoiesis in HIV-infected adults after highly active antiretroviral therapy.

Authors:  M L Markert; A P Alvarez-McLeod; G D Sempowski; L P Hale; J M Horvatinovich; K J Weinhold; J A Bartlett; T A D'Amico; B F Haynes
Journal:  AIDS Res Hum Retroviruses       Date:  2001-11-20       Impact factor: 2.205

5.  Thymic volume is associated independently with the magnitude of short- and long-term repopulation of CD4+ T cells in HIV-infected adults after highly active antiretroviral therapy (HAART).

Authors:  E Ruiz-Mateos; A Rubio; A Vallejo; R De la Rosa; A Sanchez-Quijano; E Lissen; M Leal
Journal:  Clin Exp Immunol       Date:  2004-06       Impact factor: 4.330

6.  Acute kidney disease due to immune reconstitution inflammatory syndrome in an HIV-infected patient with tuberculosis.

Authors:  Carine Salliot; Isabelle Guichard; Eric Daugas; Marie Lagrange; Jérôme Verine; Jean-Michel Molina
Journal:  J Int Assoc Physicians AIDS Care (Chic)       Date:  2008-07-14

7.  Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome.

Authors:  Graeme Meintjes; Robert J Wilkinson; Chelsea Morroni; Dominique J Pepper; Kevin Rebe; Molebogeng X Rangaka; Tolu Oni; Gary Maartens
Journal:  AIDS       Date:  2010-09-24       Impact factor: 4.177

Review 8.  HIV-1 tuberculosis-associated immune reconstitution inflammatory syndrome.

Authors:  Rachel P J Lai; Graeme Meintjes; Robert J Wilkinson
Journal:  Semin Immunopathol       Date:  2015-09-30       Impact factor: 9.623

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.